VEEV

VEEV

USD

Veeva Systems Inc. Class A Common Stock

$282.160-7.840 (-2.703%)

Reaalajas hind

Healthcare
Health Information Services
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$290.000

Kõrge

$291.690

Madal

$278.260

Maht

1.27M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

46.1B

Tööstusharu

Health Information Services

Riik

United States

Kauplemisstatistika

Keskmine maht

1.43M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $176.41Praegune $282.160Kõrge $291.69

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 12. juuni 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

VEEV: Veeva Systems Inc. Class A Common Stock – Unpacking Recent Trends & Future Possibilities

Stock Symbol: VEEV Generate Date: 2025-06-12 02:08:35

Let's break down what's been happening with Veeva Systems and what the data might be telling us.

The Latest Buzz: News Sentiment

The news flow around Veeva has been overwhelmingly positive lately. We're seeing multiple announcements about major wins and strategic moves. For instance, over 50 medtech companies, including big names, are now using Veeva MedTech for clinical trials. That's a huge vote of confidence.

Then there's the report showing 88% of medtech firms are prioritizing postmarket quality modernization, a space where Veeva clearly plays a big role. Plus, they've teamed up with Sarah Cannon Research Institute for oncology trials and secured Astellas as a global standard for their CRM. These aren't small deals; they show Veeva is deepening its roots with key players in the life sciences and healthcare sectors.

Even analyst firms like Mizuho and Needham are jumping in, raising their price targets for VEEV. This kind of consistent positive news, especially with big client wins and industry trends aligning, creates a strong sense of optimism around the company.

Price Check: What the Stock Chart Says

Looking at the last 30 days, Veeva's stock (VEEV) has seen some interesting moves. Back in mid-March, it was hovering around the $230-$240 range. Things got a bit choppy in early April, dipping below $220, but then it started a steady climb.

The real action happened around May 29th. After announcing fiscal Q1 2026 results, the stock saw a significant jump, breaking out of its previous range. It went from the mid-$230s to well over $270, even touching close to $290. This kind of sharp upward movement, especially on earnings news, often indicates strong investor reaction.

Currently, the stock is trading around $288.55 (as of June 11th's close). This puts it near its 52-week high of $291.68, which is a strong position. The average daily volume has also picked up, especially during that late May surge, showing increased interest.

Now, what about the future? AIPredictStock.com's AI model suggests a positive lean. It predicts a slight movement today (0.00%), followed by a 1.55% increase tomorrow, and a more substantial 4.04% jump the day after. This aligns with the recent upward trend and the positive news.

Putting It All Together: Outlook & Strategy Ideas

Given the strong positive news sentiment, the recent significant upward price movement, and the AI's predictions for continued gains, the near-term leaning for VEEV appears to be quite positive. It seems to favor potential buyers, suggesting a possible 'accumulate' window, especially if there's any minor pullback.

Potential Entry Consideration: If you're thinking about VEEV, the current price area, around $283.92 to $284.95, could be interesting. Why? The AI model highlights the current price being very close to a support level ($283.87), which often acts as a floor, suggesting a potential buying opportunity. The overall positive momentum from news and analyst upgrades also supports this.

Potential Exit/Stop-Loss Consideration: For managing risk, a stop-loss around $255.77 might be considered. This level is well below recent significant lows and would help protect against a sharp reversal if the positive trend doesn't hold. On the upside, if the stock continues its climb as predicted, a take-profit target around $301.61 could be a point to watch, aligning with the AI's projected upward trend and analyst targets.

Company Context

It's important to remember that Veeva Systems operates squarely in the "Health Information Services" sector, providing cloud-based software specifically for the global life sciences industry. This means their success is deeply tied to the ongoing digital transformation and regulatory needs of pharmaceutical, biotech, and medtech companies. The recent news about clinical trials, postmarket quality, and CRM adoption directly reflects their core business and its growth drivers. Their P/E ratio is on the higher side at 42.68, which is common for growth companies in specialized tech sectors, but it's something to keep in mind.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks involves risks, and past performance is not indicative of future results. Always conduct your own thorough research and consult with a qualified financial professional before making any investment decisions.

Seotud uudised

PR Newswire

Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech...

Vaata rohkem
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
PR Newswire

Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech...

Vaata rohkem
Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech
PR Newswire

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality...

Vaata rohkem
New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years
PR Newswire

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality...

Vaata rohkem
New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years
PR Newswire

Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials

Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in...

Vaata rohkem
Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials
PR Newswire

Astellas Chooses Veeva Vault CRM as Global Standard

Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and...

PR Newswire

Astellas Chooses Veeva Vault CRM as Global Standard

Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and...

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 13. juuni 2025, 01:09

LangevNeutraalneTõusev

61.7% Kindlus

Risk ja kauplemine

Riskitase1/5
Madal risk
Sobib
Konservatiivne
Kauplemisjuhend

Sisenemispunkt

$283.92

Võta kasum

$301.61

Peata kahjum

$255.77

Põhitegurid

PDI 4.1 on MDI 3.8 kohal ADX-iga 8.5, mis viitab tõusutrendile
Praegune hind läheneb tugitasemele ($283.87), tasub jälgida
Kauplemismaht on 6.3x keskmisest (21,268), mis viitab äärmiselt tugevale ostusurvele
MACD -0.0709 on signaalijoone -0.0203 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.